PTC (NASDAQ: PTC) will release its fiscal 2026 first quarter and on Wednesday, February 4 th after the stock market closes.

Conference draws participants from more than 60 countries; demand for leadership programs reaches capacity From sold ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...

PTC Therapeutics (PTCT) beats 2025 revenue guidance, details Evrysdi royalties and Sephience growth, and sets 2026 outlook.

PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw ...

PTC (NASDAQ: PTC) today announced new artificial intelligence (AI) capabilities for its FlexPLM® retail product lifecycle ...

Founded in 1985, the Boston, Massachusetts-based PTC Inc. (PTC) provides software solutions and services globally that aid ...

PTC Therapeutics faces pivotal FDA decisions for Translarna and Vatiquinone, with outcomes uncertain while both approvals are potentially transformative for long-term revenues. The Novartis ...

PTC (PTC) is drawing investor attention after a recent stretch of weaker share performance, with the stock showing declines ...

Shares of PTC Inc. PTC shed 1.18% to $171.52 Friday, on what proved to be an all-around great trading session for the stock ...

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like PTC (NASDAQ:PTC). While profit isn't the sole metric that should be ...